- Home
- YSXT vs ANL Comparison
YSXT vs ANL Comparison
Compare YSXT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YSXT | ANL |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | China | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 52.0M |
| IPO Year | 2024 | 2023 |
Fundamental Metrics
Financial Performance| Metric | YSXT | ANL |
|---|---|---|
| Price | $2.33 | $1.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 594.7K | 10.1K |
| Earning Date | 07-31-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $71,452,736.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.70 | ★ N/A |
| Revenue Growth | ★ 22.04 | N/A |
| 52 Week Low | $1.68 | $1.10 |
| 52 Week High | $9.96 | $2.99 |
Technical Indicators
Market Signals| Indicator | YSXT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 30.41 |
| Support Level | $1.96 | $1.32 |
| Resistance Level | $2.20 | $1.59 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 34.68 | 0.00 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.